靶向药物尼妥珠单抗用于Ⅳ期结直肠癌根治术后患者维持治疗的疗效及预后分析

摘要

目的 探讨靶向药物尼妥珠单抗用于Ⅳ期结直肠癌根治术后患者维持治疗的疗效及预后.方法 选取2010年1月至2012年6月本院收治的66例Ⅳ期结直肠癌患者作为研究对象,所有患者给予结直肠癌的标准方案进行一线化疗,在结直肠癌病灶化疗取得最大缩小率后,分为A组(n=34,同意接受单药尼妥珠单抗维持治疗)及B组(n=32,未接受维持治疗则停药随访观察).比较两组患者的肿瘤治疗效果、预后情况以及不良反应情况.结果 A组的总有效率及疾病控制率均显著高于B组,差异均有统计学意义(均P＜ 0.05).A组3年无瘤生存率为61.00％,B组为52.30％,A组3年无瘤生存率显著高于B组(Log-rank P=0.032).A组5年总生存率为71.20％,B组为55.50％,A组5年总生存率显著高于B组(Log-rank P=0.049).A组不良反应总发生率与B组比较,差异无统计学意义(P＞0.05).结论 靶向药物尼妥珠单抗用于Ⅳ期结直肠癌根治术后患者维持治疗的疗效较好,可提高3年无瘤生存率及5年总生存率,且未见增加不良反应发生率,值得进一步临床研究探讨.%Objective To investigate the therapeutic effect and prognosis of nimotuzumab in maintenance treatment of patients with colorectal cancer after radical operation.Methods 66 patients with stage Ⅳ colorectal cancer treated in our hospital from January 2011 to June 2012 were enrolled in this study.All patients were given standard first-line chemotherapy for colorectal cancer.After the maximum reduction rate of tumor was obtained,they were assigned to two groups.Group A (n =34)received maintenance treatment with nimotuzumab and group B (n =32) did not receive maintenance therapy.Clinical efficacy,prognosis and toxicity were compared between the two groups.Results The total effective rate and disease control rate were higher in group A than in group B (all P ＜0.05).The 3-year disease-free survival rate was significantly higher in group A than in the group B (Log-rank P =0.032).The 5-year total survival rate ofthe group A was significantly higher than that in group B (Log-rank P =0.049).There was no significant difference in the total incidence of adverse reactions between group A and group B (P ＞ 0.05).Conclusion The therapeutic effect of Nimotuzumab is favorable in maintenance treatment of patients with stage Ⅳ colorectal cancer after radical operation.It can increase the 3-year disease-free survival rate and 5-year total survival rate without increasing the incidence rate of adverse reactions.